KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Assets: 2010-2024

Historic Assets for Rigel Pharmaceuticals (RIGL) over the last 15 years, with Dec 2024 value amounting to $164.0 million.

  • Rigel Pharmaceuticals' Assets rose 73.96% to $242.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $242.5 million, marking a year-over-year increase of 73.96%. This contributed to the annual value of $164.0 million for FY2024, which is 39.88% up from last year.
  • According to the latest figures from FY2024, Rigel Pharmaceuticals' Assets is $164.0 million, which was up 39.88% from $117.2 million recorded in FY2023.
  • Rigel Pharmaceuticals' 5-year Assets high stood at $167.3 million for FY2021, and its period low was $110.4 million during FY2020.
  • Moreover, its 3-year median value for Assets was $134.3 million (2022), whereas its average is $138.5 million.
  • In the last 5 years, Rigel Pharmaceuticals' Assets declined by 25.20% in 2020 and then skyrocketed by 51.60% in 2021.
  • Yearly analysis of 5 years shows Rigel Pharmaceuticals' Assets stood at $110.4 million in 2020, then soared by 51.60% to $167.3 million in 2021, then decreased by 19.75% to $134.3 million in 2022, then dropped by 12.70% to $117.2 million in 2023, then surged by 39.88% to $164.0 million in 2024.